Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia

International Journal of Clinical Pharmacy
Jorge Enrique Machado-Alba, Manuel Enrique Machado-Duque

Abstract

Background Chronic myeloid leukemia (CML) has a low incidence but a high burden of disease, and is treated with high-cost tyrosine kinase inhibitors (TKI). Objective To determine the time from the start of a first-line TKI until it passes to second-line, and to establish the reasons for the change of therapy time. Setting Patients with Philadelphia-positive CML treated with some TKI. Methods Retrospective cohort study, between January 1 2007 and July 31 2015, with information obtained from medical records, the time to change initial drugs to secondline therapy, and the reasons for change, were identified. Kaplan-Meier survival analysis was carried out. Main outcome measure A change in therapy to the secondline TKI and the final reason for the change of therapy. Results A total of 247 patients treated were found in 22 cities in Colombia with a mean age of 53.2 ± 15.2 years. The drug most used as initial therapy was imatinib; 53.8% of cases had to change to another TKI. 50% of patients changed therapy in 42 months, men in 24 and women in 67 months (95% CI 14.314-33.686; p = 0.001). Being male (OR 2.23; 95% CI 1.291-3.854; p = 0.004) and receiving hydroxyurea (OR 3.65; 95% CI 1.601-8.326; p = 0.002) were associated with a higher p...Continue Reading

References

Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Jul 20, 2007·The New England Journal of Medicine·Charles A Schiffer
Jul 31, 2007·Lancet·Rüdiger HehlmannUNKNOWN European LeukemiaNet
Oct 12, 2010·Thyroid : Official Journal of the American Thyroid Association·Theo D KimPhilipp le Coutre
Feb 25, 2011·International Journal of Hematology·Tetsuichi YoshizatoMineo Kurokawa
Feb 7, 2014·Journal of Hematology & Oncology·Dianne PulteUNKNOWN GEKID Cancer Survival Working Group
Mar 14, 2014·Revista brasileira de hematologia e hemoterapia·Maria Helena de AlmeidaDulce Couto
May 23, 2014·Drug Discovery Today. Technologies·Stefan BalabanovTim H Brümmendorf
Aug 8, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·David D StenehjemDiana I Brixner
Dec 9, 2014·Lancet·Jane F Apperley
Apr 18, 2015·Journal of the Egyptian National Cancer Institute·Wael Abdelgawad Edesa, Raafat Ragaey Abdel-malek
Dec 3, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Mehrdad PayandehEdris Sadeghi

❮ Previous
Next ❯

Citations

Sep 24, 2020·Pharmacology Research & Perspectives·Juan-Sebastian Franco, David Vizcaya

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.